• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

7.250 +0.370 (+5.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aardvark Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Deadline Soon: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Today 15:00 EDT
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Today 10:40 EDT
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit
Today 7:10 EDT
From The Shareholders Foundation, Inc.
Via Business Wire
News headline image
Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD
August 24, 2026
San Diego, California--(Newsfile Corp. - August 24, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class... 
Via Newsfile
Topics Initial Public Offering Lawsuit
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action
August 24, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action
August 24, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
August 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action
August 21, 2026
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
August 21, 2026
From The DJS Law Group
Via Business Wire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
August 20, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
August 20, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
August 20, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
August 20, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
August 20, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
August 18, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) to Contact the Firm to Learn About Their Legal Rights
August 18, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
News headline image
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.
August 17, 2026
From Robbins LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights
August 17, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
August 16, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
August 14, 2026
From Robbins LLP
Via Business Wire
News headline image
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 09, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 24, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 17, 2026
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap